David H. Vesole MD PhD

Co-Chief, Myeloma Division; Director, Myeloma Research, John Theurer Cancer Center; Director, Myeloma Program, Medstar Georgetown University Hospital

Join to view full profile

92 2nd StHackensack, NJ 07601
Phone+1 551-996-8704
Fax+1 551-996-0582

Dr. Vesole is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vesole's full profile Already have an account?

Summary

Dr. David Vesole is an oncology specialist based in Hackensack, NJ, with extensive experience in hematologic oncology, multiple myeloma, , amyloidosis, Waldenstrom's macroglobulinemia, Car T cell therapy and hematopoietic stem cell transplantation. He completed his medical education at Northwestern University The Feinberg School of Medicine, followed by residency and fellowship training at University of Iowa Hospitals and Clinics. Dr. Vesole currently serves as a Professor of Medicine at MedStar Georgetown University Hospital and at Hackensack Meridian School of Medicine and Co-Chief of the Myeloma Division at John Theurer Cancer Center at Hackensack University Medical Center. His research includes multiple publications on multiple myeloma and related conditions, and he is involved in multiple clinical trials focused on plasma cell dyscrasia and stem cell transplantation. He has received CMS Meaningful Use Stage 1 and Stage 2 Certifications from Epic Systems Corporation.

Education & Training

University of Iowa Health Care Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1990
University of Iowa Health Care Medical CenterResidency, Internal Medicine, 1984 - 1987
Northwestern University The Feinberg School of MedicineClass of 1984

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

DC State Medical License 2012 - 2027
GA State Medical License 2025 - 2027
MD State Medical License 2018 - 2027
NJ State Medical License 2009 - 2027
NY State Medical License 2005 - 2027
IL State Medical License 1985 - 2011
WI State Medical License 1996 - 2009
IA State Medical License 1984 - 2005
AR State Medical License 1990 - 2004
American Board of Internal Medicine Internal Medicine
ABIMHematology
ABIMMedical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017

Clinical Trials

Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers Start of enrollment: 1997 Sep 01
Unknown status
Phase 2
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma Start of enrollment: 2010 Apr 08
COMPLETED
PHASE3
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Start of enrollment: 2010 Jun 16
TERMINATED
PHASE3

Publications & Presentations

PubMed

Quad-Exposed/Refractory Multiple Myeloma: Patients Previously Treated With Anti-CD38, IMiDs, Proteasome Inhibitors, and BCMA-Targeted Therapies.
Magdalena Olszewska-Szopa, David H Vesole, Artur Jurczyszyn
Clinical Lymphoma, Myeloma & Leukemia. 2026-07-01
Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.
Lili Zhang, Ayrton Bangolo, Behzad Amoozgar, Sarvarinder Gill, Jiahe Zhao
Cancers. 2026-06-19
Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.
Ajay K Nooka, Christopher Strouse, Sarah M Larson, Alexander Lesokhin, Asya Varshavsky-Yanovsky
Cancer. 2026-06-01

Journal Articles

Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Myo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Final Outcomes of Escalated Melphalan 280 mg/m2 with Amifostine Cytoprotection Followed Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: High C...
Neal Flomenberg, Dianna S Howard, Barry R Meisenberg, Parameswaran Hari, Gordon L Phillips, David H Vesole, Jasleen Randhawa, Aaron P Rapoport, Nature

Abstracts/Posters

Busulfan, Melphalan, and Bortezomib Compared to Single Agent High-Dose Melphalan As a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Mu...
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sustained Hematopoietic Recovery after Salvage Autologous Stem Cell Transplants after Long Term Storage of Cryopreserved Hematopoietic Progenitor Stem Cells (HPSC)
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
David H. Vesole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Recent Advancements and Future Directions in Frontline Treatment of Multiple MyelomaJuly 11th, 2022
John Theurer Cancer Center Investigators Present Pioneering Research at the American Society of Hematology Annual ConferenceDecember 9th, 2021
John Theurer Cancer Center and MedStar Georgetown University Hospital Announce 100August 4th, 2017

Committees

Member, ASCO Plasma Cell Educational Committee 2015 - Present
Member, ASCO Clinical Practice Guidelines Committee 2015 - Present
Nominating Committee, American Society of Blood and Marrow Transplant 2015 - Present
Data Audit Committee, Federation for The Accreditation of Cellular Therapy 2014 - Present
Accreditation Committee, Federation for The Accreditation of Cellular Therapy